Early Phase 1 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged between 18 and 75 years, male or female.
- People who have had surgery to remove a lung tumour that was confirmed by laboratory testing to be non-small cell lung cancer (NSCLC), who also tested positive for a specific gene change called an EGFR mutation, whose cancer came back or spread after treatment with a type of targeted therapy (EGFR-TKI), and who have declined chemotherapy or other treatments.
- People from whom around 5 tumour tissue samples can be collected through surgery, biopsy, or a procedure called bronchoscopy, so that a specialised type of immune cell treatment can be prepared from their own tumour.
- People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale (ECOG scale), meaning they are able to carry out at least some daily activities (confirm with trial site).
- People whose haemoglobin (a measure of red blood cells) is at or above a certain level, and who are able to receive a blood transfusion if needed.
- People whose liver, kidney, heart, and lung function fall within acceptable ranges, including specific blood test results for kidney function, liver enzymes, and bilirubin, as well as an oxygen level above 90% (confirm with trial site for exact values).
- People who are expected to live for more than 3 months and who have complete medical records available.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer diagnosis includes a type called small cell lung cancer.
- People who have previously had an organ transplant or certain treatments to reduce the size of tumours, including procedures to remove lymph nodes.
- People who are currently receiving immunotherapy or steroid-based medicines.
- People who have a serious or ongoing infection that cannot be brought under control.
- People who have a serious autoimmune disease or a condition where the immune system does not work properly from birth.
- People who have had a severe allergic reaction to biological medicines in the past, including antibiotics.
- People with active hepatitis B or hepatitis C, based on specific virus and antibody test results (confirm with trial site for exact thresholds).
- People with HIV infection or syphilis.
- Female patients who are pregnant, breastfeeding, or planning to become pregnant within 12 months.
- People who, in the opinion of the trial doctor, have any other condition that could increase the risk of harm to them or affect the reliability of the trial results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
According to the incidence of treatment-related adverse events (AEs) to evaluate the safety of Tumor-Infiltrating Lymphocytes (TILs) combined with third-Generation EGFR-TKI therapy for TKI-Resistant advanced Non-Small Cell Lung Cancer (NSCLC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.